First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Abstract

SummaryBackgroundMany patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients.MethodsTOPICAL was a double-blind, randomised, placebo-controlled, phase 3 trial, done at 78 centres in the UK. Eligibility criteria were newly diagnosed, pathologically confirmed NSCLC; stage IIIb or IV; chemotherapy naive; no symptomatic brain metastases; deemed unsuitable for chemotherapy because of poor (≥2) Eastern Cooperative Oncology Group performance status or presence of several comorbidities, or both; and estimated life expectancy of at least 8 weeks. Patients were randomly assigned (by phone call, in a 1:1 ratio, stratified by disease stage, performance status, smoking history, and centre, block size 10) to receive oral placebo or erlotinib (150 mg per day) until disease progression or unacceptable toxicity. Investigators, clinicians, and patients were masked to assignment. The primary endpoint was overall survival. Analyses were by intention to treat, and prespecified subgroup analyses included development of a rash due to erlotinib within 28 days of starting treatment. This study is registered, number ISRCTN 77383050.FindingsBetween April 14, 2005, and April 1, 2009, we randomly assigned 350 patients to receive erlotinib and 320 to receive placebo. We followed up patients until March 31, 2011. 657 patients died; median overall survival did not differ between groups (erlotinib, 3·7 months, 95% CI 3·2–4·2, vs placebo, 3·6 months, 3·2–3·9; unadjusted hazard ratio [HR] 0·94, 95% CI 0·81–1·10, p=0·46). 59% (178 of 302) of patients assigned erlotinib and who were assessable at 1 month developed first-cycle rash, which was the only independent factor associated with overall survival. Patients with first-cycle rash had better overall survival (HR 0·76, 95% CI 0·63–0·92, p=0·0058), compared with placebo. Compared with placebo, overall survival seemed to be worse in the group that did not develop first-cycle rash (1·30, 1·05–1·61, p=0·017). Grade 3 or 4 diarrhoea was more common with erlotinib than placebo (8% [28 of 334] vs 1% [four of 313], p=0·0001), as was high-grade rash (23% [79 of 334] vs 2% [five of 313], p<0·0001); other adverse events were much the same between groups.InterpretationPatients with NSCLC who are deemed unsuitable for chemotherapy could be given erlotinib. Patients who develop a first-cycle rash should continue to receive erlotinib, whereas those who do not have a rash after 28 days should discontinue erlotinib, because of the possibility of decreased survival.FundingCancer Research UK, Roche.

Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience

“…The multivariate analysis in this study showed that patients with stage IV disease had a higher risk for death than stage IIIb which is consistent with other studies, whereas the initial clinical stage affects the success of second-line chemotherapy 11,14 . From our study we observed that patients who had received platinum based as first-line treatment followed by taxanes containing regimen as second-line treatment had a better prognosis than others.…”

“…Some studies showed no difference in time to progression and OS between younger and elder patients (>70years) 12,13 . Others obtained a higher risk of death in patients aged 65 and older ones 14,15 . This discrepancy may be attributed to the small sample size of the current study.…”

Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review

“…In two trials evaluating an egfr tki compared with placebo in patients not suitable for chemotherapy, no clear differences in pfs or os were observed ( Table i). Statistical significance was reached in the trial by Lee et al 35 for pfs, but neither trial showed a difference in os 30,35 . Quality of life in the Goss et al 30 trial was not different between the two arms.…”

Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma

“…Compelling clinical examples include epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements (1,2). In both cases, patients with EGFR-mutant or ALK-rearranged advanced NSCLC are now routinely treated with kinase inhibitors (erlotinib or crizotinib, respectively) as opposed to chemotherapy as their initial systemic treatment for advanced cancer (3)(4)(5)(6). Several additional subsets of patients with NSCLC defined by an oncogenic driver genomic alteration, including mutations in BRAF and ERBB2 and rearrangements in ROS1 and RET, are similarly being treated in clinical trials to determine whether kinase inhibitors for these oncogenic proteins may represent an effective treatment approach (7)(8)(9)(10)(11).…”